DELiver Therapeutics
1 known investors
Deliver Therapeutics discovers and develops small molecule kinase inhibitors using display enumeration library (DEL) technology, targeting cancer indications including Ph+ acute lymphocytic leukemia and age-related diseases. The company's pipeline includes best-in-class multi-kinase inhibitors and senomorphic therapies designed to overcome drug resistance and regulate inflammatory pathways in aging.
BiotechHealthtechLongevity